aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Adenios focuses on developing, manufacturing, and distributing drugs that control the blood/brain barrier. Their mission is to innovate drug delivery technologies for treating central nervous system disorders such as Alzheimer's, Parkinson's, brain cancer, and multiple sclerosis.
Adenios has made significant strides in CNS disorder treatments, contributing to advancements in medical research and patient care. Their impact is evident in the improved management of complex neurological conditions, positioning them as a key player in the biotech industry.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Drug Delivery
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Adenios founded?
Adenios was founded in 2009.
Where is Adenios’s headquarters located?
Adenios’s headquarters is located in Ithaca, NY, US.
When was Adenios’s last funding round?
Adenios’s most recent funding round was for $810k (USD) in February 2010.
How many employees does Adenios have?
Adenios has 6 employees as of Feb 5, 2024.
How much has Adenios raised to-date?
As of July 05, 2023, Adenios has raised a total of $810k (USD) since Feb 16, 2010.
Add Comparison
Total Raised to Date
$810k
USD
Last Update Feb 16, 2010
Last Deal Details
$810k
USD
Feb 16, 2010
Series Unknown
Total Employees Over Time
6
As of Feb 2024
Adenios Address
401 East St
Ithaca,
New York
14850
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts